Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Myelination induction by … - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white matter injury.

Artikel i vetenskaplig tidskrift
Författare Claire-Marie Rangon
Anne-Laure Schang
Juliette Van Steenwinckel
Leslie Schwendimann
Sophie Lebon
Tingting Fu
Libo Chen
Veronique Beneton
Nathalie Journiac
Pierrette Young-Ten
Thomas Bourgeois
Johanna Maze
Boris Matrot
Ana A Baburamani
Veena Supramaniam
Carina Mallard
Lionel Trottet
A David Edwards
Henrik Hagberg
Bobbi Fleiss
Jingjun Li
Tsu Tshen Chuang
Pierre Gressens
Publicerad i Brain, behavior, and immunity
Volym 74
Sidor 265-276
ISSN 1090-2139
Publiceringsår 2018
Publicerad vid Institutionen för neurovetenskap och fysiologi
Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi
Sidor 265-276
Språk en
Länkar dx.doi.org/10.1016/j.bbi.2018.09.01...
Ämneskategorier Neurovetenskaper


Fifteen million babies are born preterm every year and a significant number suffer from permanent neurological injuries linked to white matter injury (WMI). A chief cause of preterm birth itself and predictor of the severity of WMI is exposure to maternal-fetal infection-inflammation such as chorioamnionitis. There are no neurotherapeutics for this WMI. To affect this healthcare need, the repurposing of drugs with efficacy in other white matter injury models is an attractive strategy. As such, we tested the efficacy of GSK247246, an H3R antagonist/inverse agonist, in a model of inflammation-mediated WMI of the preterm born infant recapitulating the main clinical hallmarks of human brain injury, which are oligodendrocyte maturation arrest, microglial reactivity, and hypomyelination. WMI is induced by mimicking the effects of maternal-fetal infection-inflammation and setting up neuroinflammation. We induce this process at the time in the mouse when brain development is equivalent to the human third trimester; postnatal day (P)1 through to P5 with i.p. interleukin-1β (IL-1β) injections. We initiated GSK247246 treatment (i.p at 7 mg/kg or 20 mg/kg) after neuroinflammation was well established (on P6) and it was administered twice daily through to P10. Outcomes were assessed at P10 and P30 with gene and protein analysis. A low dose of GSK247246 (7 mg/kg) lead to a recovery in protein expression of markers of myelin (density of Myelin Basic Protein, MBP & Proteolipid Proteins, PLP) and a reduction in macro- and microgliosis (density of ionising adaptor protein, IBA1 & glial fibrillary acid protein, GFAP). Our results confirm the neurotherapeutic efficacy of targeting the H3R for WMI seen in a cuprizone model of multiple sclerosis and a recently reported clinical trial in relapsing-remitting multiple sclerosis patients. Further work is needed to develop a slow release strategy for this agent and test its efficacy in large animal models of preterm infant WMI.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?